Available IPD datapackage for study 'A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB068, a Bruton's Tyrosine Kinase Inhibitor, in Healthy Subjects'

The primary objective of the study is to evaluate the safety and tolerability of single oral
doses of BIIB068 in healthy participants. Secondary objectives are to characterize the
single-oral-dose Pharmacokinetic (PK) of BIIB068 in healthy participants, to determine the
effect of food on the single-oral-dose PK of BIIB068 in healthy participants and to examine
the effect of administration of the proton pump inhibitor (PPI) esomeprazole on the
single-dose PK of BIIB068 in healthy participants.